The Latest Breaking News from Pfizer

Pfizer Recalls Some Batches Of Another Hypertension Drug Over Cancer-Causing Impurity

Pfizer Inc (NYSE:PFE) said it is voluntarily recalling five batches of its Accupril blood pressure tablets after finding elevated levels of a potential cancer-causing agent in the medicine. Accupril is indicated for hypertension to lower blood pressure. It is also indicated for the management of heart failure as adjunctive therapy when added to…

Benzinga · Apr 25, 2022

The quest for a coronavirus supervaccine

PARIS: As vaccine makers rush to stamp out new Covid-19 variants, some scientists have set their sights higher, aiming for a universal coronavirus vaccine that could tackle any future strains and possibly even stave off another pandemic.

Bangkok Post · Apr 25, 2022

COVID shots still work but researchers hunt new improvements

COVID-19 vaccines still offer strong protection against severe illness and death, but Moderna and Pfizer are testing combination shots as a possible new kind of booster

The Independent UK · Apr 24, 2022

If You Invested $1,000 In BioNTech Stock At Its Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga · Apr 22, 2022

WHO 'Strongly Recommends' Pfizer's Covid Pill

The World Health Organization said Friday it "strongly recommended" Pfizer's Covid-19 antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization. However the UN agency warned it was "extremely concerned" that the inequality in access seen with Covid vaccines would…

Asharq Al-Awsat · Apr 22, 2022

‘Best therapeutic choice’: WHO backs Pfizer’s COVID antiviral

UN health body says Paxlovid ‘strongly recommended’ for patients with non-severe disease at risk of hospital admission.

Al Jazeera · Apr 22, 2022

If You Invested $1,000 In Pfizer Stock At Its Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga · Apr 21, 2022

Latest data shows significant rise in Covid deaths in England and Wales for third week in a row

Deaths involving Covid-19 are up 13 per cent on last week, the latest data shows

Manchester Evening News · Apr 21, 2022

Covid booster gives long-lasting protection, study finds

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

Wales Online · Apr 21, 2022

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

The Independent UK · Apr 21, 2022